Focused Ultrasound for Parkinson Disease

Phase-Based Progress Estimates
Neurological Associates of West Los Angeles, Los Angeles, CA
Parkinson Disease+2 More
Focused Ultrasound - Device
All Sexes
What conditions do you have?

Study Summary

The purpose of this Phase I open label study is to evaluate longer term tolerability and potential effectiveness of transcranial ultrasound in people with tremor as a results of Parkinson's Disease or Essential Tremor.

Eligible Conditions

  • Parkinson Disease
  • Familial Tremor
  • Tremor

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Parkinson Disease

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Through Completion of Study (Average time 8-weeks)

Through Completion of Study (Average time 8-weeks)
9 Hole Pegboard Task (9 HPT)
Essential Tremor Rating Assessment Scale (TETRAS)
Parkinson's Activities of Daily Living Scale (PAD-L)

Trial Safety

Safety Progress

1 of 3

Other trials for Parkinson Disease

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Focused Ultrasound · No Placebo Group · Phase < 1

Experimental Group · 1 Intervention: Focused Ultrasound · Intervention Types: Device
First Studied
Drug Approval Stage
How many patients have taken this drug
Focused Ultrasound
Completed Phase 1

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through completion of study (average time 8-weeks)
Closest Location: Neurological Associates of West Los Angeles · Los Angeles, CA
Photo of Los Angeles 1Photo of Los Angeles 2Photo of Los Angeles 3
2020First Recorded Clinical Trial
1 TrialsResearching Parkinson Disease
2 CompletedClinical Trials

Who is running the clinical trial?

Neurological Associates of West Los AngelesLead Sponsor
24 Previous Clinical Trials
3,957 Total Patients Enrolled
1 Trials studying Parkinson Disease
100 Patients Enrolled for Parkinson Disease
Sheldon Jordan, MDPrincipal InvestigatorThe Regenesis Project
12 Previous Clinical Trials
2,590 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old.
You have an age of at least 90 years.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.